Cancer Biological Therapy Market Size, Revenue Share, Drivers & Trends Analysis, 2024–2028


Cancer biological therapy, also known as immunotherapy or targeted therapy, represents a paradigm shift in cancer treatment, leveraging the body’s immune system or specific molecular targets to selectively destroy cancer cells while sparing healthy tissues. Over the past decade, biological therapies have revolutionized cancer care, offering improved efficacy, reduced toxicity, and prolonged survival for patients with various malignancies. The cancer biological therapy market continues to evolve rapidly, driven by groundbreaking research, technological innovations, and increasing adoption in clinical practice. This article provides a comprehensive analysis of the dynamics shaping the cancer biological therapy market, including key trends, challenges, recent advancements, and future prospects.

Market Overview:

The global cancer biological therapy market size was significantly large in 2020 and is expected to continue to register a rapidly inclining revenue CAGR between 2021 and 2028. Key factors responsible for driving market revenue growth are rising cancer frequency, increased spending in R&D to improve therapeutic effectiveness, increased spending, and surging awareness of cancer and its available therapies.

Cancer biological therapy, an advanced cancer treatment approach, utilizes living organisms to target and destroy cancer cells. These organisms may be engineered in a laboratory or naturally occurring within the body. Terms such as biotherapy, biological response modifier therapy, and immunotherapy are commonly used to describe this treatment modality. Cancer biological therapy harnesses the body’s immune system to recognize and eliminate cancer cells. Examples include vaccinations, monoclonal antibodies, interferons, and interleukins. This therapy leverages the immune system directly or indirectly to combat cancer, reducing side effects associated with certain chemotherapy drugs and targeting specific substances on cancer cells for elimination.

The global market for cancer biological therapy has seen remarkable growth, driven by factors such as the increasing prevalence of cancer, rising demand for personalized medicine, and the expanding range of therapeutic applications for biological agents. Biological therapies encompass various modalities, including monoclonal antibodies, immune checkpoint inhibitors, targeted small molecules, cytokine therapies, and adoptive cell therapies. Each of these approaches is designed to exploit specific vulnerabilities in cancer cells or modulate the immune response against tumors.

Get a sample of the report @ 

Market Drivers:

  1. Precision Medicine and Personalized Therapies: Biological therapies enable a precision medicine approach to cancer treatment, targeting specific molecular alterations or immune checkpoints implicated in tumor growth and survival. Biomarker-driven patient selection, molecular profiling, and companion diagnostic tests optimize treatment outcomes by identifying patients most likely to benefit from biological agents, thereby reducing unnecessary exposure to toxicities and improving response rates.
  2. Immune Checkpoint Inhibitors Revolutionize Cancer Treatment: Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies and anti-CTLA-4 antibodies, have transformed the landscape of cancer therapy across multiple malignancies, including melanoma, lung cancer, bladder cancer, and renal cell carcinoma. By unleashing the immune system’s ability to recognize and attack cancer cells, ICIs induce durable responses, long-term survival benefits, and unprecedented outcomes in patients with advanced or metastatic disease.
  3. Targeted Therapies for Genomic Alterations: Targeted therapies directed against specific genetic mutations or signaling pathways driving cancer growth have emerged as effective treatment options for patients with molecularly defined tumors. Small molecule inhibitors, antibody-drug conjugates, and kinase inhibitors selectively target oncogenic drivers such as EGFR, ALK, BRAF, HER2, and ROS1, providing tailored treatment approaches and improved survival outcomes in molecularly stratified patient populations.
  4. Regulatory Approvals and Market Expansion: Regulatory approvals for novel biological therapies and expanded indications for existing agents have fueled market growth and innovation in cancer treatment. Regulatory agencies such as the FDA and EMA have granted accelerated approvals, breakthrough designations, and priority review status to promising biological agents, expediting their development, evaluation, and commercialization.

Market Challenges:

  1. Immunotherapy Resistance and Treatment Failures: Despite the remarkable success of immunotherapy in certain cancer types, a significant proportion of patients do not respond to treatment or develop resistance over time. Tumor-intrinsic and microenvironmental factors, immune evasion mechanisms, and heterogeneity in immune cell populations contribute to treatment failures, highlighting the need for predictive biomarkers, combination strategies, and rational drug design approaches to overcome resistance.
  2. Immune-Related Adverse Events (irAEs): Immune checkpoint inhibitors can induce immune-related adverse events (irAEs) affecting various organ systems, including the skin, gastrointestinal tract, liver, endocrine glands, and lungs. Managing irAEs requires prompt recognition, interdisciplinary collaboration, and immunosuppressive therapy to mitigate symptoms, prevent complications, and maintain treatment efficacy while minimizing treatment interruptions or discontinuations.
  3. High Cost and Access Barriers: The high cost of biological therapies poses challenges for patient access, reimbursement, and healthcare sustainability, particularly in resource-limited settings or underinsured populations. Affordability issues, insurance coverage limitations, and disparities in healthcare access contribute to inequities in cancer care, underscoring the need for value-based pricing, cost-effectiveness analyses, and innovative reimbursement models to ensure equitable access to life-saving therapies.

Market Trends:

  1. Combination Therapies and Rational Drug Combinations: Combination strategies combining biological agents with conventional chemotherapy, radiation therapy, targeted therapies, or other immunomodulatory agents aim to enhance treatment efficacy, overcome resistance mechanisms, and improve patient outcomes. Rational drug combinations based on complementary mechanisms of action, synergistic effects, and biomarker-driven selection offer potential for maximizing therapeutic benefits and minimizing toxicities.
  2. Development of Next-Generation Biological Therapies: Ongoing research efforts focus on the development of next-generation biological therapies, including bispecific antibodies, antibody-drug conjugates, CAR-T cell therapies, oncolytic viruses, and cancer vaccines. These innovative modalities target novel antigens, exploit alternative immune pathways, or enhance the tumor-targeting specificity and potency of biological agents, expanding the therapeutic armamentarium against cancer.
  3. Biomarker Discovery and Predictive Modeling: Advances in genomics, proteomics, and bioinformatics enable the identification of predictive biomarkers, treatment response signatures, and patient stratification algorithms for guiding personalized cancer therapy. Biomarker-driven clinical trials, real-world data analyses, and machine learning algorithms facilitate precision oncology approaches, optimizing treatment selection, and clinical decision-making in diverse patient populations.

Future Perspectives:

The cancer biological therapy market is poised for continued growth and innovation, driven by advances in molecular profiling, targeted drug development, and immune-based therapies. Emerging trends such as combination therapies, next-generation biological agents, and predictive modeling hold promise for further improving treatment outcomes, prolonging survival, and ultimately transforming cancer into a manageable chronic disease.

Request a customization of the report @ 


Cancer biological therapy represents a paradigm shift in cancer treatment, offering personalized, targeted, and immunomodulatory approaches to combatting the complex biology of malignancy. Despite challenges such as treatment resistance, immune-related toxicities, and cost constraints, biological therapies have revolutionized cancer care and significantly improved patient outcomes across a broad spectrum of cancer types. By embracing innovative strategies, leveraging scientific advances, and prioritizing patient-centered care, stakeholders in the cancer biological therapy market can continue to advance the frontiers of cancer treatment and bring hope to millions of patients worldwide.

Explore additional Reports:

Sodium Formate Market @

Virtual Pipeline System Market @

Polypropylene Glycol Ethers Market @

Mesh Nozzle Plates Market @

Calcium Hydride Market @

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:

Direct Line: +1-212-710-1370


Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @

Browse More Latest Reports @

Leave a Reply

Your email address will not be published. Required fields are marked *